Craven House investee Bio Vitos gets acquisition approval
Craven House Capital PLC - London-based investment fund with minority shareholding in four Swedish-managed eCommerce and pharmaceutical businesses - Says its investee company Bio Vitos has received... London-based investment fund, Craven House Capital PLC, has received approval from Nasdaq Stockholm to acquire shares in Hemcheck Sweden AB for its investment in four Swedish-managed eCommerce and pharmaceutical businesses. The company, Bio Vitos, will now proceed with the transaction and will own 259.7 million Hemcheck shares, or an 88% stake, upon completion. The acquisition of these shares is contingent on the successful completion of this transaction. Currently, the current stock price in London is up 7.1% compared to USD0.23 on Monday, a significant increase for the 12-month period.
Veröffentlicht : vor 2 Jahren durch MarketScreener in Finance
Craven House Capital PLC - London-based investment fund with minority shareholding in four Swedish-managed eCommerce and pharmaceutical businesses - Says its investee company Bio Vitos has received approval from Nasdaq Stockholm to acquire shares in Hemcheck Sweden AB. This follows conditional approval being granted in late August. Bio Vitos will now proceed with completing the transaction, Craven House says. Upon completion, Bio Vitos will own 259.7 million Hemcheck shares, or an 88% stake. Craven House has a 25% stake in Bio Vitos.
Current stock price: USD0.23, up 7.1% in London on Monday morning
12-month change: up sharply from USD0.11
Themen: Markets